Indication
Philadelphia Positive Acute Lymphoblastic Leukemia
2 clinical trials
3 products
2 drugs
Clinical trial
A Phase Ib Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)Status: Recruiting, Estimated PCD: 2024-01-31
Product
Ascentage Pharma HQP1351Product
BlinatumomabClinical trial
Efficacy and Safety of Molecular Targeted Therapy Combined With Chemotherapy and Sequential CAR-T Cells in Newly Diagnosed Adult Patients With Philadelphia Chromosome-Positive B-cell Acute Lymphoblastic LeukemiaStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Drug
CAR-T cellsProduct
VenetoclaxDrug
Olverembatinib